Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leukemia therapy Medicare rates

Executive Summary

HHS would create a separate Medicare hospital diagnosis- related group (DRG 492) for chemotherapy patients with acute leukemia to reflect their more costly care versus nonleukemia cancer patients, under proposed changes to the DRG system published in the June 3 Federal Register. DRG 492's price would be about five times more than DRG 410 under the proposal. The DRG revisions were advocated by Cetus with support from Health Technology Associates and Fox, Bennett and Turner. HTA found that the median treatment cost for DRG 410 patients is $ 3,203, while patients with leukemias or testicular cancer cost $ 6,000 or more, and those with acute nonlymphocytic leukemia cost $ 14,488.
Advertisement
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS019268

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel